46,986 T2D patients with an average age of 61 years, of which 59% were male, previously on metformin monotherapy, who initiated an additional glucose-lowering agent (GLP-1 RA, SGLT-2i, DPP4i, SU, or insulin) in the period 2010-2016. The gene discussed is GCG; the disease is type 2 diabetes mellitus.